Taro Tokita

Sumitomo Mitsui Banking Corp. engages in the provision of financial services centered on banking. It operates through the following business segments: Wholesale, Retail, International, Market Sales, and Headquarters Management. The Wholesale segment covers business for customers of large and medium-sized companies in Japan. The Retail segment handles business for domestic individuals and SME customers. The International segment comprises of business for overseas Japanese and non-Japanese companies. The Market Sales segment corresponds to financial market business. The Headquarters Management segment includes all other businesses not covered by other segments. The company was founded in April 2001 and is headquartered in Tokyo, Japan.

Ginsen Co., Ltd. engages in the general insurance agency, life insurance agency, building, parking lots and real estate consulting businesses. The company was founded in May 1954 and is headquartered in Osaka, Japan.

DX Antenna Co. Ltd. manufactures antenna and other networking equipment. The firm’s products include optical transmitters/receivers, BS antennas, CS antennas, CS/BS multi-beam antennas, wireless LAN antennas, CS/BS receivers, headend devices, two way CATV amplifiers, channel proper amplifiers, converters, level controllers, UHF antennas, VHF antennas, FM antennas, amateur radio antennas, and mixer/band separators. The company was founded on August 1, 1953 and is headquartered in Kobe-shi, Japan.

Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California.

REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan.

WITH Corp. engages in development, publishing, and distribution of audio books, educational toys, and promotional products. It also engages in the plan, manufacture and module process of electronic components. The company was founded on June 21, 1976 and is headquartered in Tokyo, Japan.

Almex PE, Inc. provides engineering and maintenance services for surface treatment equipment. It also manufactures and distributes chemical products. The company was founded in June 1966 and is headquartered in Kanuma, Japan.

Whiz Partners, Inc. (Whiz Partners) is an independent venture capital firm headquartered in Tokyo, Japan. It became a separate entity from its former brand, CSK Venture Capital Co., Ltd. The firm was founded by Toshio Ando, Atsushi Matsumura, and Junichi Kajimoto in 2010.

Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto.

CellAxia, Inc. is a Japanese company that engages in research and development, manufacturing, and selling of pharmaceutical products. The company is based in Tokyo, Japan. The company was founded in 2017 by Makoto Seki.

Adaptate Biotherapeutics Ltd. engages in research and experimental development on biotechnology. The company was founded on August 21, 2019 and is headquartered in London, the United Kingdom.

IgniteEye Corp. engages in the provision of cloud services for recruitment activities. Its cloud products include SONAR, Compass, Sniping and CREATIVE. The company was founded by Takashi Yoshida in May 2013 and is headquartered in Tokyo, Japan.

Axcelead Drug Discovery Partners, Inc. is a Japanese company founded in 2017 that provides services for the quality evaluation of new modality regenerative medical cells, effectiveness and safety evaluation of target cells, and bridging data. The company is based in Fujisawa, JP. and has subsidiaries in the United States. It is used by more than 100 facilities such as clients pharmaceutical companies, venture companies, and academia. Axcelead offers non-clinical development strategic planning and problem resolution services to its clients.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.